Compare MBIN & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | PRCT |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | MBIN | PRCT |
|---|---|---|
| Price | $42.07 | $27.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $43.67 | $35.44 |
| AVG Volume (30 Days) | 218.2K | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | $31.76 | $32.85 |
| Revenue Next Year | $3.73 | $24.66 |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $27.25 | $19.35 |
| 52 Week High | $48.50 | $64.89 |
| Indicator | MBIN | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 48.91 |
| Support Level | $30.89 | $19.35 |
| Resistance Level | $48.50 | $29.24 |
| Average True Range (ATR) | 1.35 | 1.86 |
| MACD | -0.32 | 0.36 |
| Stochastic Oscillator | 38.93 | 71.60 |
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.